Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram et al. · CA A Cancer Journal for Clinicians · 2018 · 86.6K citations · Full text

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 28.6K citations

Surgical Oncology, Recist Guideline, Medicine +9

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Axel Grothey, Eric Van Cutsem, Alberto Sobrero et al. · The Lancet · 2012 · 2.8K citations

Oncology, Gastrointestinal Oncology, Regorafenib Monotherapy +9

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

Stuart Pocock, Richard Simon · Biometrics · 1975 · 2.3K citations

Prognostic Factors, Sequential Treatment Assignment, Patient Selection +19

The rapid assessment of fatigue severity in cancer patients

Tito R. Mendoza, X. Shelley Wang, Charles S. Cleeland et al. · Cancer · 1999 · 1.7K citations · Full text